Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calypte Biomedical

This article was originally published in The Gray Sheet

Executive Summary

Urine-based HIV-1 screening test manufacturer and FDA will discuss accelerating development of a new rapid HIV urine test during a pre-IDE meeting scheduled for early October. Preliminary data indicate 100% sensitivity and specificity, the firm claims. Calypte has an agreement with SA Scientific to develop and manufacture the test at its San Antonio facilities, while Calypte will manage the clinical trials (1"The Gray Sheet" Dec. 3, 2001, In Brief)...
Advertisement

Related Content

Calypte Biomedical
Advertisement
UsernamePublicRestriction

Register

MT017077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel